The subsidiary of Liaoning Chengda (600739.SH) plans to invest 5 million US dollars to subscribe to private equity fund shares

According to Zhitong Finance App News, Liaoning Chengda (600739.SH) issued an announcement. In order to better implement the company's strategic plan and seize investment opportunities in the biomedical sector in a timely manner, Chengda Steel Hong Kong, a wholly-owned subsidiary of the company, plans to invest 5 million US dollars as a limited partner to subscribe to the fund share of Likon Venture Fund II Limited Partnership (Cayman) (“Target Fund” for short).

The total amount raised by the target fund is not less than 60 million US dollars, and the initial fundraising scale is not less than 35 million US dollars. The general partner is Likon Fortune iILTD. (Cayman), the fund management company is Elikon Advisors Inc. The main business of the target fund is equity investment in start-ups in the biomedical and healthcare industries, and also takes into account equity investment in growing companies. The above investment targets include, but are not limited to, innovative drugs and enterprises in the upstream and downstream industries, medical devices, medical diagnostic equipment and reagents, and related services. After the investment is completed, the target fund will not be included in the scope of the company's consolidated statements.